Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction


Among patients with stable HFrEF, empagliflozin for 12 weeks reduced pulmonary capillary wedge pressure (PCWP) compared with placebo. There was no significant improvement in cardiac index or PCWP/cardiac index at rest or exercise.

Omar M, Jensen J, Frederiksen PH, et al. J Am Coll Cardiol 2020;76:2740–51.